Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
SOLO Pharmaco-imaging: Preclinical Translational imaging
Non-invasive preclinical imaging to monitor the target expression and in vivo target engagement, the biodistribution of compounds, the effect of therapeutic treatments, and for the assessment of radiopharmaceuticals and translational biomarkers in precision medicine.
Access to multimodal imaging equipment, adapted to rodents and non-human primates
Optical imaging bioluminescence, fluorescence
Functional imaging MRI, DCE-MRI
Nuclear imaging PET, SPECT,combined MRI/TEP
Radiolabeling of chemicals or biological molecules (peptides, antibodies or other entities) adapted to study their fate and effects.
A dedicated expertise to design and perform specific pharmaco-imaging studies for your preclinical research programs – in various therapeutic areas – using technologies identical to those used in clinical nuclear medicine.